In our view, Abbott is the clear winner in this deal.

Although the strategic rationale for combining Boston Scientific and Guidant appears compelling, we have lingering concerns.

We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.

Don't count BSX out yet. We expect BSX to continue to pursue GDT by potentially modifying or increasing its $72/share offer.

We believe that Boston Scientific can raise its offer to $78 a share and still maintain an investment-grade credit rating.

If you're not going to offend somebody you don't need the First Amendment.